FDA Noxafil Approval Delayed By Last-Minute Label, Data Integrity Issues
This article was originally published in Pharmaceutical Approvals Monthly
FDA overshot the user fee goal on Schering-Plough’s Noxafil (posaconazole) to address labeling and data integrity issues that arose late in the review of the antifungal, FDA review documents indicate.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class